1. 何志培. 甚麼是思覺失調症?高雄醫師會誌. 24(3): 243-249.
2. Dean L. Schizophrenia. https://www.ncbi.nlm.nih.gov/books/NBK62008/.
Accessed Jan 03, 2019.
3. 思覺失調症.
https://aileenlin.gitbooks.io/intern-handout/content/C1-3/2.3.shizophrenia.html.
Accessed Jan 03, 2019.
4. 精神科藥物介紹.
http://stud.adm.ncku.edu.tw/stu/speach/992speech/0720%E7%B2%BE%E7%A5
%9E%E7%A7%91%E8%97%A5%E7%89%A9%E4%BB%8B%E7%B4%B9.p df. Accessed Jan 03, 2019.
5. Grover S, Chakrabarti S, Parmanand Kulhara, Avasthi A. Clinical Practice Guidelines for Management of Schizophrenia. Indian J Psychiatry. 2017 Jan;59(Suppl 1):S19-S33.
6. First-Generation Antipsychotics: An Introduction
https://psychopharmacologyinstitute.com/antipsychotics/first-generation-antipsy chotics/. Accessed Jan 03, 2019.
7. 張文和. 精神分裂症治療之選藥原則.台灣精神醫學 2005; 19(4): 264-281.
8. Lally J, MacCabe JH. Antipsychotic medication in schizophrenia: a review.
British medical bulletin 2015; 114(1): 169-179.
9. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2012; 13(5):
318-378.
10. The National Institute for Health and Care. Excellence. Psychosis and schizophrenia in adults: prevention and management
https://www.nice.org.uk/guidance/cg178/chapter/1-Recommendations. Accessed Jan 03, 2019.
11. Diefenderfer LA, Iuppa C. Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder. Ment Health Clin. 2018 Mar
23;7(5):207-212.
12. WHO Collaborating Centre for Drug Statistics Methodology.
https://www.whocc.no/atc_ddd_index/?code=N05AX. Accessed Jan 04, 2019.
13. 衛生福利部食品藥物管理署. 衛生福利部食品藥物管理署之西藥、醫療器 材、含藥化妝品許可證.
https://www.fda.gov.tw/MLMS/(S(cazgpazof2ugdyvjtn0jlq24))/H0001.aspx.
Accessed Jan 04, 2019.
14. Canadian Agency for Drugs and Technologies in Health. Brexpiprazole.
https://www.cadth.ca/brexpiprazole. Accessed Jan 08, 2019.
15. Pharmaceutical Benefits Scheme. Brexpiprazole: Tablet 1 mg, Tablet 2 mg, Tablet 3 mg, Tablet 4 mg; Rexulti® .
http://search.health.gov.au/s/search.html?query=brexpiprazole&collection=health
&profile=pbs&Submit=. Accessed Jan 08, 2019.
16. National Institute for Health and Care Excellence.
https://www.nice.org.uk/search?q=brexpiprazole. Accessed Jan 09, 2019.
17. Scottish Medicines Consortium.
https://www.scottishmedicines.org.uk/search/?keywords=brexpiprazole.
Accessed Jan 09, 2019.
18. Kane JM, Skuban A, Ouyang J, et al. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophrenia Research 2015; 164(1-3): 127-135.
19. Correll CU, Skuban A, Ouyang J, et al. Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial. The American journal of psychiatry 2015; 172(9):
870-880.
20. Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. International clinical psychopharmacology 2016; 31(4): 192-201.
21. Fleischhacker WW, Hobart M, Ouyang J, et al. Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study. The international journal of neuropsychopharmacology 2017; 20(1): 11-21.
22. Ishigooka J, Iwashita S, Tadori Y. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study. Psychiatry Clin Neurosci. 2018 Sep;72(9):692-700.
23. Kishi T, Oya K, Matsui Y, et al. Comparison of the efficacy and safety of 4 and 2 mg/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials. Neuropsychiatric disease and treatment 2018; 14: 2519-2530.
24. Ng-Mak D, Tongbram V, Ndirangu K, Rajagopalan K, Loebel A. Efficacy and metabolic effects of lurasidone versus brexpiprazole in schizophrenia: a network meta-analysis. J Comp Eff Res. 2018 Apr 26. doi: 10.2217/cer-2018-0016. [Epub
ahead of print]
25. Citrome L. Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? International journal of clinical practice 2015; 69(9): 978-997.
26. Aigbogun MS, Liu S, Kamat SA, Sapin C, Duhig AM, Citrome L. Relapse prevention: a cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. ClinicoEconomics and outcomes research : CEOR 2018; 10: 443-456.
27. 102 年-106 年全民健康保險醫療統計. 衛生福利部統計處.
https://dep.mohw.gov.tw/DOS/np-1918-113.html. Accessed January 4, 2019.
28. 2017 年國人全民健康保險就醫疾病資訊. 中央健康保險署.
file:///C:/Users/schuang870/Downloads/2017%E5%B9%B4%E5%9C%8B%E4
%BA%BA%E5%85%A8%E6%B0%91%E5%81%A5%E5%BA%B7%E4%BF
%9D%E9%9A%AA%E5%B0%B1%E9%86%AB%E7%96%BE%E7%97%85%
E8%B3%87%E8%A8%8A-1070906.pdf. Accessed January 4, 2019.
29. Citrome L, Ota A, Nagamizu K, Perry P, Weiller E, Baker RA. The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study. International clinical psychopharmacology 2016; 31(4): 192-201.
附錄
附錄一 藥品給付規定內容
1.2.精神治療劑 Psychotherapeutic drugs
1.2.1.選擇性血清促進素再吸收抑制劑 (SSRI)、血清促進素及正腎上腺素再吸 收抑制劑 (SNRI)及其他抗憂鬱劑（fluvoxamine maleate、fluoxetine、
paroxetine、sertraline、venlafaxine、milnacipran、mirtazapine、citalopram、
escitalopram、duloxetine、agomelatine、vortioxetine 等製劑）：(88/12/1、
89/10/1、91/5/1、92/6/1、93/5/1、94/2/1、94/12/1、99/10/1、101/7/1、107/3/1) 使用時病歷上應詳細註明診斷依據及使用理由。
1.2.1.1.Bupropion HCL：(92/1/1、99/10/1) 作為戒菸治療者不予給付。
1.2.2.抗精神病劑 Antipsychotics 1.2.2.1.Clozapine（如 Clozaril）
1.限精神科專科醫師使用。
2.前 18 週使用時，每週需作白血球檢驗，每次處方以七日為限，使用 18 週後，每月作一次白血球檢驗。
3.申報費用時，應檢附白血球檢驗報告。
1.2.2.2.Second generation antipsychotics ( 簡 稱 第 二 代 抗 精 神 病 藥 品 ， 如 clozapine、olanzapine、risperidone、quetiapine、amisulpride、ziprasidone、
aripiprazole、paliperidone、lurasidone 等)：(91/9/1、92/1/1、92/7/1、94/1/1、
95/10/1、97/5/1、99/10/1、106/1/1)
1.本類製劑之使用需符合下列條件(95/10/1、97/5/1、99/10/1、106/1/1)：
(1)開始使用「第二代抗精神病藥品」時需於病歷記載：
醫療理由或診斷，以及臨床整體評估表 (Clinical Global Impression，簡 稱 CGI) 之分數。
(2)經規則使用六至八週後，需整體評估其療效，並於病歷記載：臨床整 體評估表之分數。
(3)日劑量超過下列治療劑量時，需於病歷記載理由：
clozapine 400 mg/day risperidone 6 mg/day olanzapine 20 mg/day quetiapine 600 mg/day
amisulpride 800mg/day (92/1/1) ziprasidone 120mg/day (92/7/1) aripiprazole 15mg/day (94/1/1) paliperidone 12mg/day (97/5/1）
lurasidone 120mg/day (106/1/1）
2.本類藥品不得使用於雙極性疾患之鬱症發作。(95/10/1)
3.Olanzapine 用於預防雙極性疾患復發時，限 lithium、carbamazepine、valproate 等藥品至少使用兩種以上，治療無效或無法耐受副作用時使用。(95/10/1)
附錄表一 療效評估文獻搜尋紀錄 PubMed
# Search Details Results
1 ("brexpiprazole"[Supplementary Concept] OR "brexpiprazole"[All Fields]) AND ("schizophrenia"[MeSH Terms] OR
"schizophrenia"[All Fields])
72
Embase
1 brexpiprazole, schizophrenia' OR (brexpiprazole, AND ('schizophrenia'/exp OR schizophrenia))
190 2 ('brexpiprazole, schizophrenia' OR (brexpiprazole, AND
('schizophrenia'/exp OR schizophrenia))) AND [humans]/lim
164 3 ('brexpiprazole, schizophrenia' OR (brexpiprazole, AND
('schizophrenia'/exp OR schizophrenia))) AND [humans]/lim AND ([article]/lim OR [article in press]/lim)
57
Cochrane Library
1 brexpiprazole, schizophrenia Cochrane Protocol 1；
Trials 54
附錄表二、經濟文獻資料庫搜尋結果
資料庫 查詢日期 關鍵字 篇數 篩選
後篇 數 PubMed 2019.1.3 1 Rexulti 131
2 brexpiprazole 131
3 schizophrenia 105,867
4 （Cost-consequence analysis）OR
（cost-benefit analysis ）OR
（cost-effectiveness analysis ） OR （cost-utility analysis） OR
（cost studies）
451,354
5 #1 OR #2 AND #3 AND #4 2 1 Embase 2019.1.3 1 Rexulti 328
2 brexpiprazole 325 3 schizophrenia 205,640 4 （Cost-consequence analysis）OR
（cost-benefit analysis ）OR
（cost-effectiveness analysis ） OR （cost-utility analysis） OR
（cost studies）
116,330
5 #1 OR #2 AND #3 AND #4 1 1 Cochrane
Library
2019.1.3 1 Rexulti 0 2 brexpiprazole 109 3 schizophrenia 13,950 4 （Cost-consequence analysis）OR
（cost-benefit analysis ）OR
（cost-effectiveness analysis ） OR （cost-utility analysis） OR
（cost studies）
16,308
5 #1 OR #2 AND #3 AND #4 1 0